Haemonetics Corp (HAE)
88.99
+0.65
(+0.74%)
USD |
NYSE |
May 28, 16:00
88.99
0.00 (0.00%)
After-Hours: 16:16
Haemonetics Research and Development Expense (TTM): 54.44M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 54.44M |
| December 31, 2023 | 54.22M |
| September 30, 2023 | 53.65M |
| June 30, 2023 | 51.88M |
| March 31, 2023 | 50.13M |
| December 31, 2022 | 47.70M |
| September 30, 2022 | 45.04M |
| June 30, 2022 | 45.00M |
| March 31, 2022 | 46.80M |
| December 31, 2021 | 44.43M |
| September 30, 2021 | 41.90M |
| June 30, 2021 | 37.81M |
| March 31, 2021 | 32.86M |
| December 31, 2020 | 30.99M |
| September 30, 2020 | 30.49M |
| June 30, 2020 | 31.15M |
| March 31, 2020 | 30.88M |
| December 31, 2019 | 30.66M |
| September 30, 2019 | 32.63M |
| June 30, 2019 | 33.80M |
| March 31, 2019 | 35.71M |
| December 31, 2018 | 38.05M |
| September 30, 2018 | 41.50M |
| June 30, 2018 | 40.44M |
| March 31, 2018 | 39.23M |
| Date | Value |
|---|---|
| December 31, 2017 | 37.46M |
| September 30, 2017 | 33.50M |
| June 30, 2017 | 34.31M |
| March 31, 2017 | 37.56M |
| December 31, 2016 | 39.38M |
| September 30, 2016 | 41.86M |
| June 30, 2016 | 45.08M |
| March 31, 2016 | 44.96M |
| December 31, 2015 | 51.04M |
| September 30, 2015 | 50.74M |
| June 30, 2015 | 50.13M |
| March 31, 2015 | 54.19M |
| December 31, 2014 | 50.80M |
| September 30, 2014 | 54.36M |
| June 30, 2014 | 58.37M |
| March 31, 2014 | 54.20M |
| December 31, 2013 | 53.94M |
| September 30, 2013 | 50.31M |
| June 30, 2013 | 46.20M |
| March 31, 2013 | 44.40M |
| December 31, 2012 | 39.44M |
| September 30, 2012 | 38.08M |
| June 30, 2012 | 37.60M |
| March 31, 2012 | 36.80M |
| December 31, 2011 | 36.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
30.49M
Minimum
Sep 2020
54.44M
Maximum
Mar 2024
41.32M
Average
43.17M
Median
Research and Development Expense (TTM) Benchmarks
| ResMed Inc | 304.81M |
| Stryker Corp | 1.417B |
| InfuSystems Holdings Inc | -- |
| Perspective Therapeutics Inc | 24.91M |
| Xtant Medical Holdings Inc | 1.689M |